- Chiasma Inc (NASDAQ:CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.
- The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
- Recently, the company announced positive patient-reported outcomes data from its MPOWERED trial, demonstrating that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs to Mycapssa.
- Price Action: CHMA shares are down 0.2% at $4.7 during the premarket session on the last check Tuesday.
JD.Com. Yum China Among Companies Selected by U.S. Regulators for Audit Inspection Starting Next Month